- Home
- DSM vs ABSI Comparison
DSM vs ABSI Comparison
Compare DSM & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- ABSI
- Stock Information
- Founded
- DSM 1989
- ABSI 2011
- Country
- DSM United States
- ABSI United States
- Employees
- DSM N/A
- ABSI N/A
- Industry
- DSM Investment Managers
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- DSM Finance
- ABSI Health Care
- Exchange
- DSM Nasdaq
- ABSI Nasdaq
- Market Cap
- DSM 301.0M
- ABSI 318.2M
- IPO Year
- DSM N/A
- ABSI 2021
- Fundamental
- Price
- DSM $5.86
- ABSI $4.35
- Analyst Decision
- DSM
- ABSI Strong Buy
- Analyst Count
- DSM 0
- ABSI 7
- Target Price
- DSM N/A
- ABSI $8.57
- AVG Volume (30 Days)
- DSM 161.7K
- ABSI 7.6M
- Earning Date
- DSM 01-01-0001
- ABSI 03-20-2025
- Dividend Yield
- DSM 3.97%
- ABSI N/A
- EPS Growth
- DSM N/A
- ABSI N/A
- EPS
- DSM N/A
- ABSI N/A
- Revenue
- DSM N/A
- ABSI $4,207,000.00
- Revenue This Year
- DSM N/A
- ABSI $8.57
- Revenue Next Year
- DSM N/A
- ABSI $169.72
- P/E Ratio
- DSM N/A
- ABSI N/A
- Revenue Growth
- DSM N/A
- ABSI N/A
- 52 Week Low
- DSM $4.69
- ABSI $2.45
- 52 Week High
- DSM $6.05
- ABSI $6.72
- Technical
- Relative Strength Index (RSI)
- DSM 47.31
- ABSI 66.14
- Support Level
- DSM $5.79
- ABSI $3.40
- Resistance Level
- DSM $5.86
- ABSI $4.01
- Average True Range (ATR)
- DSM 0.05
- ABSI 0.43
- MACD
- DSM 0.01
- ABSI 0.07
- Stochastic Oscillator
- DSM 70.53
- ABSI 97.13
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.